Viracta Therapeutics (VIRX)
(Delayed Data from NSDQ)
$0.81 USD
-0.03 (-3.55%)
Updated May 3, 2024 04:00 PM ET
After-Market: $0.84 +0.03 (3.68%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.81 USD
-0.03 (-3.55%)
Updated May 3, 2024 04:00 PM ET
After-Market: $0.84 +0.03 (3.68%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum D VGM
Zacks News
Has IMARA (IMRA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how IMARA Inc. (IMRA) and Viracta (VIRX) have performed compared to their sector so far this year.
Does Sunesis (VIRX) Have the Potential to Rally 335% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 334.8% upside potential for Sunesis (VIRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Viracta (VIRX) Up on Orphan Drug Tag for Peripheral Lymphoma
by Zacks Equity Research
Viracta (VIRX) receives Orphan Drug designation from the European Commission for its lead candidate Nana-val for treating peripheral T-cell lymphoma. Stock up.
Here's Why Viracta Therapeutics (VIRX) is Up So Far This Year
by Zacks Equity Research
Viracta Therapeutics' (VIRX) Nana-val is being evaluated in multiple clinical studies in various subtypes of EBV-associated cancers.
Here's Why Assertio Holdings (ASRT) Stock is Up This Year
by Zacks Equity Research
Assertio Holdings' (ASRT) successful execution of its restructuring plan, resulting in significant cost savings, is boosting profits.
Zacks Industry Outlook Highlights Chinook Therapeutics, Assertio Holdings, Viracta Therapeutics and Soleno Therapeutics
by Zacks Equity Research
Chinook Therapeutics, Assertio Holdings, Viracta Therapeutics and Soleno Therapeutics are part of Zacks Industry Outlook article.
4 Small Stocks to Bet on in an Upbeat Drugs Industry
by Kinjel Shah
It is expected that innovation will continue to drive growth in the Medical-Drugs industry in 2022. KDNY, ASRT, VIRX, SLNO may prove to be good additions to one's portfolio.